Annexon Inc (NASDAQ: ANNX) has experienced a rise in its stock price by 11.74 compared to its previous closing price of 2.47. However, the company has seen a gain of 6.15% in its stock price over the last five trading days. globenewswire.com reported 2025-03-03 that Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License Application (BLA) Submission Established Groundbreaking Global Registration Path for ANX007 to be Potential First Vision-Preserving Treatment for Dry AMD with GA in Europe and U.S.; Topline Phase 3 ARCHER II Data Expected Second Half 2026 First-in-Kind Oral C1s Inhibitor POC Trial Ongoing with Dosing in Three Patients with Cold Agglutin Disease; Expanded ANX1502 Dataset to Include Up to Seven Patients Expected Mid-2025 Strong Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $312 Million as of December 31, 2024, and Anticipated Runway into Second Half 2026 BRISBANE, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2024 financial results.
Is It Worth Investing in Annexon Inc (NASDAQ: ANNX) Right Now?
The 36-month beta value for ANNX is also noteworthy at 1.14. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ANNX is 95.34M, and at present, short sellers hold a 10.59% of that float. The average trading volume of ANNX on March 06, 2025 was 1.37M shares.
ANNX’s Market Performance
The stock of Annexon Inc (ANNX) has seen a 6.15% increase in the past week, with a -21.59% drop in the past month, and a -48.79% fall in the past quarter. The volatility ratio for the week is 11.19%, and the volatility levels for the past 30 days are at 8.28% for ANNX. The simple moving average for the past 20 days is -4.96% for ANNX’s stock, with a -48.98% simple moving average for the past 200 days.
Analysts’ Opinion of ANNX
Many brokerage firms have already submitted their reports for ANNX stocks, with JP Morgan repeating the rating for ANNX by listing it as a “Overweight.” The predicted price for ANNX in the upcoming period, according to JP Morgan is $11 based on the research report published on March 01, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ANNX reach a price target of $6, previously predicting the price at $4. The rating they have provided for ANNX stocks is “Buy” according to the report published on December 21st, 2023.
Wells Fargo gave a rating of “Overweight” to ANNX, setting the target price at $11 in the report published on October 30th of the previous year.
ANNX Trading at -29.71% from the 50-Day Moving Average
After a stumble in the market that brought ANNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.14% of loss for the given period.
Volatility was left at 8.28%, however, over the last 30 days, the volatility rate increased by 11.19%, as shares sank -25.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.24% lower at present.
During the last 5 trading sessions, ANNX rose by +6.15%, which changed the moving average for the period of 200-days by -38.67% in comparison to the 20-day moving average, which settled at $2.90. In addition, Annexon Inc saw -46.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANNX starting from Dananberg Jamie, who sale 5,521 shares at the price of $2.96 back on Feb 18 ’25. After this action, Dananberg Jamie now owns 33,479 shares of Annexon Inc, valued at $16,342 using the latest closing price.
ARTIS DEAN RICHARD, the EVP & CHIEF SCIENTIFIC OFFICER of Annexon Inc, sale 5,515 shares at $2.97 during a trade that took place back on Feb 18 ’25, which means that ARTIS DEAN RICHARD is holding 83,814 shares at $16,380 based on the most recent closing price.
Stock Fundamentals for ANNX
The total capital return value is set at -0.48. Equity return is now at value -50.84, with -42.67 for asset returns.
Based on Annexon Inc (ANNX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -4.07.
Currently, EBITDA for the company is -154.07 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.37.
Conclusion
In summary, Annexon Inc (ANNX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
